Gains First-in-Class Norovirus Vaccine Candidate and Virus-Like Particle Platform,
Advancing Takeda’s Commitment to Vaccines and Global Public Health
Osaka, Japan, Oct. 5, 2012, Deerfield, Ill. and Bozeman, Mont., Oct. 4, 2012, – Takeda Pharmaceutical
Company Limited (Takeda) and LigoCyte Pharmaceuticals, Inc. jointly announced today that Takeda’s
wholly-owned subsidiary, Takeda America Holdings, Inc. and LigoCyte Pharmaceuticals, Inc. have entered into a definitive agreement for Takeda to acquire LigoCyte for an upfront payment of $60 million, with future contingent consideration based on the progress of development projects. LigoCyte is a privately-held biopharmaceutical company specializing in innovative vaccine products headquartered in Bozeman, Montana.
[button url=”/wp-content/uploads/2012/12/Takeda-Acquires-LigoCyte-Pharmaceuticals-Inc-.pdf” target=”_blank” size=”small” style=”skyblue” ]Download Press release[/button]